Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

Enzolytics, Inc. (ENZC)

0.0007
0.0000
(0.00%)
At close: April 23 at 3:01:12 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ENZC

Recent News: ENZC

View More
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator

Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
ACCESS Newswire 7 months ago
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement

Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
ACCESS Newswire 7 months ago
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells

Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
ACCESS Newswire 7 months ago
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications

Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
ACCESS Newswire 8 months ago
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.

Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
ACCESS Newswire 8 months ago
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release

Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
ACCESS Newswire 8 months ago

SAGALIUM RESPONDS TO COMPETITOR’S FALSE AND MISLEADING PRESS RELEASE
GlobeNewswire 8 months ago
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment

Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
ACCESS Newswire 9 months ago
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology

Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
ACCESS Newswire 10 months ago
Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation

Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation
ACCESS Newswire 10 months ago
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment

Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
ACCESS Newswire 11 months ago
View More

Related Tickers

HALB Halberd Corporation
0.0017
-5.56%
 
ENDV Endonovo Therapeutics, Inc.
0.0003
0.00%
 
TXTM ProText Mobility, Inc.
0.0007
-12.50%
 
APRE Aprea Therapeutics, Inc.
1.5000
-2.60%
 
NBY NovaBay Pharmaceuticals, Inc.
0.5772
-1.27%
 
RNAZ TransCode Therapeutics, Inc.
0.3140
+1.00%
 
BRTX BioRestorative Therapies, Inc.
1.7300
+0.58%
 
UNCY Unicycive Therapeutics, Inc.
0.6342
+1.75%
 
VINC Vincerx Pharma, Inc. Common Stock
0.2750
+7.34%
 
OGEN Oragenics, Inc.
0.1940
+3.74%